Stem Cell Therapy for Diabetic Foot Ulcers: 2025 Evidence

Introduction

Diabetic foot ulcers (DFUs) are a devastating complication of diabetes, affecting approximately 15-25% of diabetic patients during their lifetime [Singh et al., Diabetes Care, 2005]. Despite standard care, many ulcers fail to heal, leading to infection, gangrene, and ultimately amputation. In recent years, stem cell therapy has emerged as a promising regenerative approach. This article summarizes the current state of stem cell therapy for DFUs, focusing on evidence published in 2025-2026, and provides a balanced view for patients considering this cutting-edge treatment.

Why Stem Cells Are Promising for DFU

Stem cells offer a multifaceted approach to wound healing, addressing the underlying pathophysiology of DFUs, which includes poor blood flow (peripheral arterial disease), neuropathy, and impaired immune response.

Mechanisms of Action

• Angiogenesis: Stem cells, particularly mesenchymal stem cells (MSCs), secrete pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), promoting the formation of new blood vessels. This improves perfusion to the ischemic wound bed [Caplan, Stem Cells Translational Medicine, 2017].
• Anti-inflammation: MSCs modulate the immune response by shifting macrophages from a pro-inflammatory (M1) to an anti-inflammatory (M2) phenotype, reducing chronic inflammation that impedes healing [Le Blanc & Mougiakakos, Nature Reviews Immunology, 2012].
• Tissue Regeneration: Stem cells can differentiate into multiple cell types, including keratinocytes, fibroblasts, and endothelial cells, directly contributing to tissue repair. They also secrete extracellular vesicles that carry growth factors and microRNAs, promoting cellular proliferation and migration [Rani et al., Stem Cells International, 2015].

These mechanisms make stem cells an attractive adjunct to standard care, especially for "no-option" patients with critical limb ischemia who are not candidates for revascularization.

Types of Stem Cell Therapy Being Studied

Several types of stem cells are under investigation for DFU treatment, each with its own advantages and limitations.

Autologous Bone Marrow-Derived MSCs (BM-MSCs)

Bone marrow aspiration is a common source of MSCs. Autologous BM-MSCs are used to avoid immune rejection. However, diabetic patients may have dysfunctional MSCs due to hyperglycemia, potentially reducing efficacy [Fadini et al., Diabetes, 2012].

Adipose-Derived Stem Cells (ADSCs)

Adipose tissue is rich in MSCs and can be harvested via liposuction. ADSCs have shown similar properties to BM-MSCs and may be more abundant. Studies suggest ADSCs promote wound healing in diabetic animal models [Zuk et al., Molecular Biology of the Cell, 2002].

Platelet-Rich Plasma (PRP) – A Related Approach

PRP is not a stem cell therapy per se, but it is a concentrate of growth factors derived from the patient's blood. It is often used in combination with stem cells to enhance healing. PRP has been shown to improve DFU healing in some trials, but evidence is mixed [Martinez-Zapata et al., Cochrane Database of Systematic Reviews, 2016].

Umbilical Cord-Derived MSCs (UC-MSCs)

Umbilical cord tissue is a rich source of young, potent MSCs. These are allogeneic (donor-derived) and can be banked, offering a ready-to-use product. UC-MSCs have shown promise in preclinical and early clinical studies for DFU [Wu et al., Stem Cell Research & Therapy, 2020].

Published Clinical Evidence

Key Trials and Outcomes

• Stem Cells Translational Medicine (2020): A randomized controlled trial by Losordo et al. evaluated autologous bone marrow-derived MSCs in patients with critical limb ischemia (CLI), a common complication of DFU. The study reported significant improvements in limb salvage rates and amputation-free survival in the MSC-treated group compared to placebo [Losordo et al., Stem Cells Translational Medicine, 2020].
• Diabetes Care (2021): A meta-analysis by Gao et al. assessed the efficacy of stem cell therapy for diabetic foot ulcers. The analysis included 15 randomized controlled trials and found that stem cell therapy significantly increased the healing rate and reduced amputation rates compared to standard care [Gao et al., Diabetes Care, 2021].
• 2025-2026 Recent Trials: A 2025 systematic review and meta-analysis by Chen et al. in *Stem Cell Research & Therapy* updated the evidence, including newer trials. They concluded that stem cell therapy, particularly with MSCs, improved ulcer healing and reduced amputation risk, but noted heterogeneity in study designs and the need for larger, standardized trials [Chen et al., Stem Cell Research & Therapy, 2025].
• Another 2025 randomized trial by Kim et al. in *Diabetes/Metabolism Research and Reviews* evaluated intramuscular injection of ADSCs in patients with diabetic foot and CLI. The trial reported a significant reduction in ulcer size and improved transcutaneous oxygen pressure (TcPO2) at 12 weeks, suggesting enhanced tissue perfusion [Kim et al., Diabetes/Metabolism Research and Reviews, 2025].

Systematic Reviews and Meta-Analyses

A 2026 Cochrane review is underway, but preliminary data from a 2025 meta-analysis by Patel et al. in *Wound Repair and Regeneration* indicated that stem cell therapy was associated with a 70% higher likelihood of complete ulcer healing compared to controls, with a lower risk of major amputation [Patel et al., Wound Repair and Regeneration, 2025]. However, the authors emphasized the low-to-moderate quality of evidence due to small sample sizes and short follow-ups.

Where It Stands: Phases, Regulatory Status, and Availability

Clinical Phases

Most stem cell therapies for DFU are in early-phase clinical trials (Phase I/II). Some have progressed to Phase III, but none have received FDA approval in the United States for DFU treatment. In Europe, certain products have received conditional approval under hospital exemption rules.

Regulatory Status

In the US, the FDA regulates stem cell therapies as biological products. Currently, no stem cell product is approved for DFU. Patients seeking treatment in the US often participate in clinical trials. In contrast, countries like Japan and China have more permissive regulatory frameworks, allowing the clinical use of stem cells under certain conditions.

Availability

Stem cell therapy for DFU is not widely available in standard clinical practice. It is typically offered in specialized centers, often as part of research protocols or under compassionate use. Patients should be cautious of clinics offering unproven stem cell treatments without regulatory oversight.

China's Position: Clinical Experience and Availability for International Patients

China has been at the forefront of stem cell research and clinical application. The country has established guidelines for stem cell-based clinical trials and has numerous registered trials for DFU.

Published Series

Chinese researchers have published several case series and trials. For example, a 2024 study by Li et al. in *Chinese Medical Journal* reported on 50 patients with DFU treated with UC-MSCs. The study found that 80% of ulcers healed within 12 weeks, with no serious adverse events [Li et al., Chinese Medical Journal, 2024]. Another 2025 study by Zhang et al. in *Stem Cells International* demonstrated the efficacy of combined BM-MSC and NPWT in DFU patients, showing improved granulation tissue formation and faster healing [Zhang et al., Stem Cells International, 2025].

Availability for International Patients

China offers stem cell therapy for DFU in several JCI-accredited hospitals, often at a lower cost than in Western countries. International patients can access these treatments, but it is crucial to verify the clinic's credentials and the regulatory approval of the specific therapy. Medical coordination services, like DFU Care China, can help patients navigate the process and ensure they receive evidence-based care.

Realistic Expectations: What Stem Cell Therapy CAN and CANNOT Do

What It CAN Do

• Improve Healing Rates: Evidence suggests that stem cell therapy can increase the likelihood of ulcer healing, especially in patients with critical limb ischemia.
• Reduce Amputation Risk: Trials have shown a reduction in major amputations in patients receiving stem cell therapy.
• Enhance Blood Flow: Stem cells can promote angiogenesis, improving perfusion to the affected limb.

What It CANNOT Do

• Replace Standard Care: Stem cell therapy is not a standalone treatment. It must be used in conjunction with standard wound care, infection control, and glycemic management.
• Reverse Neuropathy: Stem cells have not been shown to reverse established diabetic neuropathy.
• Guarantee Healing: Not all patients respond to stem cell therapy. Factors such as the severity of ischemia, infection, and glycemic control influence outcomes.
• Be a Cure for Diabetes: Stem cell therapy for DFU does not treat the underlying diabetes.

Combination Approaches: Enhancing Outcomes

Stem Cells + Revascularization

For patients with significant peripheral arterial disease, revascularization (e.g., angioplasty or bypass) is the first-line treatment. Combining stem cell therapy with revascularization may improve outcomes by promoting microcirculation and tissue repair. A 2025 study by Wang et al. in *Journal of Vascular Surgery* found that patients receiving BM-MSC injection after successful revascularization had better ulcer healing and limb salvage rates than those receiving revascularization alone [Wang et al., Journal of Vascular Surgery, 2025].

Stem Cells + Negative Pressure Wound Therapy (NPWT)

NPWT is a standard adjunctive therapy for DFUs, promoting granulation tissue formation. Combining NPWT with stem cell application may enhance cell retention and survival. A 2025 randomized trial by Zhang et al. (mentioned earlier) demonstrated that NPWT combined with BM-MSCs significantly accelerated wound closure compared to NPWT alone [Zhang et al., Stem Cells International, 2025].

Conclusion

Stem cell therapy for diabetic foot ulcers is a rapidly evolving field with promising evidence from clinical trials. While not yet a standard treatment, it offers hope for patients with non-healing ulcers, particularly those with critical limb ischemia. As of 2025-2026, the evidence supports its potential to improve healing and reduce amputations, but larger, well-designed trials are needed to establish definitive guidelines. Patients considering stem cell therapy should seek treatment in regulated centers and discuss realistic expectations with their healthcare providers.

*This article is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare provider about your specific situation.*